Related Experiment Video
Updated: Jun 25, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Characterization of monoclonal antibodies directed against squamous cell carcinoma antigens: report of the second
K Nustad1, O Nilsson, K Majnesjö
1Department of Medical Biochemistry, Radiumhospitalet, Rikshospitalet HF, Oslo, Norway. kjell.nustad@radiumhospitalet.no
Abstract:
Eight monoclonal antibodies directed against Squamous Cell Carcinoma Antigens (A1 and A2) were collected and evaluated by three working groups. Recombinant antigens, fusion proteins and native antigens from normal tissue were used to evaluate antibody specificity. Five antibodies reacted with both A1 and A2. Two of these antibodies (K123 and K131) showed related binding characteristics, whereas SCC140, K182 and SCC111 demonstrated unique epitope specificity and were not related to the reference antibodies included (F1H3, F2H7 and SCC107). SCC111 reacted particularly well with antigen on Western blot, indicating that the epitope was partly hidden when the antigen was in solution. Two antibodies (SCC103 and SCC109) reacted only with A2 and the fusion protein A1/A2, indicating that they recognized an A2 epitope in exon 8. The A2-specific antibodies are unique in their binding to A2 and are different from the reference antibodies included (SCC104 and K122). SCC103 is probably the best A2-specific antibody available. One antibody, K136, was A1-specific and is related to reference antibody K135. The new antibodies can be used to establish immunometric assays for specific measurement of A1, A2 or both A1 and A2 together.
Insights
Eight new monoclonal antibodies targeting Squamous Cell Carcinoma Antigens (SCCAs) A1 and A2 were characterized. Several antibodies demonstrated unique specificities, enabling potential development of precise immunometric assays for cancer biomarker detection.
Area of Science:
- Immunology
- Biochemistry
- Oncology
Background:
- Squamous Cell Carcinoma Antigens (SCCAs) A1 and A2 are important biomarkers in cancer diagnostics.
- Development of specific antibodies is crucial for accurate detection and monitoring of SCCAs.
Purpose of the Study:
- To evaluate and characterize eight novel monoclonal antibodies against SCCAs A1 and A2.
- To assess the specificity and epitope mapping of these new antibodies.
- To determine their potential utility in developing immunometric assays.
Main Methods:
- Antibody specificity was assessed using recombinant antigens, fusion proteins, and native antigens.
- Western blot analysis was employed to evaluate antigen binding characteristics.
- Comparison with established reference antibodies was performed.
Main Results:
- Five antibodies recognized both SCCAs A1 and A2.
- Three antibodies (SCC140, K182, SCC111) exhibited unique epitope specificities.
- Two antibodies (SCC103, SCC109) were specific for SCCA A2, with SCC103 showing high specificity.
- One antibody (K136) was specific for SCCA A1.
Conclusions:
- Novel monoclonal antibodies with distinct specificities for SCCAs A1 and A2 have been identified.
- These antibodies, particularly SCC103 for A2, offer potential for developing highly specific immunometric assays.
- The characterized antibodies can advance the precise measurement of SCCAs in clinical settings.
